Loading...
•
Mar 31, 2023
Maravai Q1 2023 Earnings Report
Reported first quarter 2023 financial results with a continued focus on expanding product portfolio, market leadership, and scientific innovation.
Key Takeaways
Maravai LifeSciences reported a first-quarter revenue of $79.0 million, a net loss of $(1.3) million, and adjusted EBITDA margins of 30.1%. The revenue decrease was primarily driven by a decline in Nucleic Acid Production revenue due to decreased COVID-19 related CleanCap demand.
Quarterly revenue was $79.0 million.
Net loss was $(1.3) million.
Adjusted EBITDA margins were 30.1%.
The company focused on expanding its product portfolio and advancing market leadership in the mRNA space.
Maravai
Maravai
Maravai Revenue by Segment
Revenue by Segment
Nucleic Acid Production Revenue
CapyFin.comBiologics Safety Testing Revenue
CapyFin.com Forward Guidance
Maravai projects total revenue for 2023 to be in the range of $400.0 million to $440.0 million. Adjusted EBITDA is expected to be in the range of $155.0 million to $175.0 million, and adjusted fully diluted EPS is expected to be in the range of $0.27 to $0.33 per share.